What do systematic reviews say?

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin receptor blockers (ARBs) vs placebo

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 226 participants
  GRADE not reported

More intensive vs less intensive insulin therapy

It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  RR 0.68 [0.29, 1.58]
  3 studies · 208 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo

Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  RR 2 [0.26, 15.37]
  2 studies · 8873 participants
  Low

Renin‐angiotensin system inhibition vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found